Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application For Al001 For Dementia Related To Alzheimer’S Pursuant To The Securities Purchase Agreement With Digital Power Lending
Round Type
Venture
AtlantaBiotechnologyHealth CareScience And EngineeringDescription
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”) announced that Digital Power Lending, LLC (“DPL”), a wholly owned subsidiary of Ault Global Holdings, Inc. (“AGH”) (NYSE American: DPW), a diversified holding company, has made an additional investment in Alzamend, a related party of AGH and early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.
Quick answer
Alzamend Neuro raised an undisclosed amount in a funding round, dated August 4, 2021. Alzamend Neuro is based in Atlanta, Georgia, United States.
- How much did Alzamend Neuro raise?
- Alzamend Neuro raised an undisclosed amount in a funding round on August 4, 2021.
- What does Alzamend Neuro do?
- Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress..
- Where is Alzamend Neuro based and how big is it?
- Alzamend Neuro is based in Atlanta, Georgia, United States. Fundz records about 7 employees.
- Who are the decision-makers at Alzamend Neuro?
- Fundz holds 1 contact at Alzamend Neuro, including the Deputy General Counsel and Vice President of Legal Affairs. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Alzamend Neuro that raised within 45 days of this round, from Fundz verified event records.
- Iaso Bio raised $108M (Series C) on September 16, 2021.
- Walking Fish Therapeutics raised $29M on September 14, 2021.
- Walking Fish Therapeutics raised $50M (Series A) on September 13, 2021.
- Neurogastrx raised $60M (Series B) on August 26, 2021.
- Psilera raised $2.5M (Seed) on August 26, 2021.
- Atavistik Bio raised $60M (Series A) on August 24, 2021.
Who to call at Alzamend Neuro, and when
A new round usually means Alzamend Neuro is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alzamend Neuro raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alzamend Neuro, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alzamend Neuro. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alzamend Neuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Alzamend Neuro raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.